| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 05/30/2002 | WO2002041896A2 Use of thienopyrimidines |
| 05/30/2002 | WO2002041882A2 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| 05/30/2002 | WO2002041880A2 Use of pyrazolo[4,3-d]pyrimidines |
| 05/30/2002 | WO2002041837A2 Treatment of mucositis |
| 05/30/2002 | WO2002041835A2 Estrogen receptor modulators |
| 05/30/2002 | WO2002022599A3 Chemokine receptor binding heterocyclic compounds |
| 05/30/2002 | WO2002020736A9 Proteases |
| 05/30/2002 | WO2001092565A8 Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription |
| 05/30/2002 | WO2001074390A3 The use of a calcium channel blocker for treating renal disorders |
| 05/30/2002 | WO2001066746A3 G-protein coupled receptor related polypeptides |
| 05/30/2002 | WO2000078952A8 Human rna metabolism proteins (rmep) |
| 05/30/2002 | WO2000066581A8 Cyanopyrroles as progesterone receptor agonists |
| 05/30/2002 | US20020065416 Anti-inflammatory agents |
| 05/30/2002 | US20020065315 For therapy and prophylaxis of asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, etc. |
| 05/30/2002 | US20020065302 Cyclic AMP-specific phosphodiesterase inhibitors |
| 05/30/2002 | US20020065296 Administering heteroarylurea compound for therapy of cytokine mediated diseases and proteolytic enzyme mediated diseases |
| 05/30/2002 | US20020065284 Dipeptide derivatives |
| 05/30/2002 | US20020065269 3-Sulfonylamino-c5 to c8-methyleneimino-2-carboxylic acid compound is effective for prophylaxis and treatment of inflammation, tissue degradation, cancer, fibrosis and related diseases |
| 05/30/2002 | US20020065233 Oral administration of Sulodexide in unit dosages suitable for the treatment of diabetic nephropathies in both macro and micro albuminic patients, producing immediate and lasting improvement in albumin excretion rate |
| 05/30/2002 | US20020064525 Anti-IgE vaccines |
| 05/30/2002 | US20020064524 Formulation for topical non-invasive application in vivo |
| 05/30/2002 | CA2429647A1 Use of thienopyrimidines |
| 05/30/2002 | CA2429645A1 Use of pyrazolo[4,3-d]pyrimidines |
| 05/30/2002 | CA2429630A1 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 05/30/2002 | CA2429579A1 Truncated cd200 |
| 05/30/2002 | CA2429442A1 Aminothiazoles and their use as adenosine receptor antagonists |
| 05/30/2002 | CA2429328A1 Substituted cyclohexane derivates and the use thereof in medicaments for treating cardiovascular diseases |
| 05/30/2002 | CA2427444A1 3-arylindole derivatives and their use as cb2 receptor agonists |
| 05/30/2002 | CA2427184A1 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| 05/30/2002 | CA2398924A1 Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof |
| 05/30/2002 | CA2363935A1 Therapy for andropause using estrogen agonists/antagonists and testosterone |
| 05/29/2002 | EP1208235A1 Abc transport polynucleotides, polypeptides, and antibodies |
| 05/29/2002 | EP1208218A2 Methods and compositions for delivery of pharmaceutical agents |
| 05/29/2002 | EP1208201A2 Compositions and methods for the treatment of immune related diseases |
| 05/29/2002 | EP1208103A2 Reverse-turn mimetics and methods relating thereto |
| 05/29/2002 | EP1208092A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor |
| 05/29/2002 | EP1207868A1 Pharmaceutical tramadol salts |
| 05/29/2002 | EP1207867A1 Oral pharmaceutical forms of administration with a delayed action |
| 05/29/2002 | EP1207866A1 Delayed-action form of administration containing tramadol saccharinate |
| 05/29/2002 | EP1207860A1 Controlled release pellet formulation |
| 05/29/2002 | EP1207858A1 Oral dosage forms |
| 05/29/2002 | EP0938329B1 Immunogenic tlp composition |
| 05/29/2002 | EP0613374B1 Lactobacillus and skim milk compositions and methods for preventing microbial urogenital infections |
| 05/29/2002 | EP0300021B2 A process for treating infertility and an agent for use in the process |
| 05/29/2002 | DE10058663A1 Verwendung von Thienopyrimidinen Use of Thienopyrimidinen |
| 05/29/2002 | DE10058662A1 Verwendung von Pyrazolo[4,3-d]pyrimidinen Use of pyrazolo [4,3-d] pyrimidines |
| 05/29/2002 | DE10028443C1 Production of optically active 3,3-diaryl-propylamine derivatives comprises six step process from 4-hydroxybenzoic acid or alkyl 4-hydroxybenzoate and cinnamic acid |
| 05/29/2002 | CN1351614A Human antibodies that bind human IL-12 and methods for producing |
| 05/29/2002 | CN1351609A Low-molecular inhibitors of complement proteases |
| 05/29/2002 | CN1351604A Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| 05/29/2002 | CN1351602A New pharmaceutically active compounds |
| 05/29/2002 | CN1351601A Heterocyclic compounds binding chemotactic factor receptor |
| 05/29/2002 | CN1351592A Acyl derivatives which treat VL4-4 related disorders |
| 05/29/2002 | CN1351591A 抗炎吲哚衍生物 Indomethacin derivative |
| 05/29/2002 | CN1350854A Full-natural medicine for treating calculus |
| 05/29/2002 | CN1085541C Chinese medicine for treating calculus hydrops of liver, gall and kidney (CN) |
| 05/29/2002 | CN1085539C Enema for rescuring patient suffering from renal syndrome-hemorrhagic feverenal failure |
| 05/28/2002 | US6395781 Reducing vascular diameter |
| 05/28/2002 | US6395764 Nosal decongestion, respiratory system disorders |
| 05/28/2002 | US6395755 Urogenital system disorders; postmenopause syndroms |
| 05/28/2002 | US6395729 Use of pyridazino[4,5-b]indole-1-acetamide derivatives for preparing medicines for treating diseases related to the dysfunction of peripheral benzodiazepin receptors |
| 05/28/2002 | CA2181377C Tetracyclic derivatives, process of preparation and use |
| 05/28/2002 | CA2118997C Benzimidazole derivatives, their preparation and use |
| 05/23/2002 | WO2002040700A2 Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| 05/23/2002 | WO2002040671A2 Immunoglobulin superfamily proteins |
| 05/23/2002 | WO2002040517A2 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | WO2002040506A2 Modified clostridial neurotoxins with altered biological persistence |
| 05/23/2002 | WO2002040485A1 Preventive or therapeutic medicines for diabetes containing fused-heterocycle compounds or their salts |
| 05/23/2002 | WO2002040476A1 Pyridyl-substituted triazoles as tgf inhibitors |
| 05/23/2002 | WO2002040475A1 Bombesin receptor antagonists |
| 05/23/2002 | WO2002040470A1 Imidazole derivatives, process for their preparation and their use |
| 05/23/2002 | WO2002040469A1 Bombesin receptor antagonists |
| 05/23/2002 | WO2002040468A1 Compounds |
| 05/23/2002 | WO2002040457A1 Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor |
| 05/23/2002 | WO2002040456A1 Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor |
| 05/23/2002 | WO2002040453A1 Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists |
| 05/23/2002 | WO2002040450A1 (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors |
| 05/23/2002 | WO2002040039A2 In vivo use of water absorbent polymers |
| 05/23/2002 | WO2002040038A2 M. tuberculosis chaperonin 10 and uses thereof |
| 05/23/2002 | WO2002040037A2 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | WO2002040019A1 Benzimidazole derivatives |
| 05/23/2002 | WO2002040007A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 05/23/2002 | WO2002039994A2 Methods for the treatment and prevention of urinary stone disease |
| 05/23/2002 | WO2001079444A3 Albumin fusion proteins |
| 05/23/2002 | WO2001079277A3 Immunogenic pili presenting foreign peptides, their production and use |
| 05/23/2002 | WO2001079180A3 5-substituted tetralones as inhibitors of ras farnesyl transferase |
| 05/23/2002 | WO2001072826A3 Oncogenic osteomalacia-related gene 1 |
| 05/23/2002 | WO2001064837A8 β NETRIN AND USES THEREOF |
| 05/23/2002 | WO2001049651A3 Aminomethyl-phenyl-cyclohexanone derivatives |
| 05/23/2002 | WO2001041760A9 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 05/23/2002 | WO2000063204A3 Substituted azoles |
| 05/23/2002 | US20020061920 Selected fused pyrrolocarbazoles |
| 05/23/2002 | US20020061918 Benzyl isooxazole and benzyl pyrazole derivatives as aldose reductase and cyclooxygenase-2 inhibitors |
| 05/23/2002 | US20020061914 Benzothiazole, benzooxazole and benzoimidazole derivatives as sodium or calcium channel modulators |
| 05/23/2002 | US20020061910 Optically pure reboxetine or its methanesulfonate salt inhibits reuptake of norepinephrine |
| 05/23/2002 | US20020061887 For therapy and prophylaxis of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis |
| 05/23/2002 | US20020061853 Caspase inhibtors and uses thereof |
| 05/23/2002 | US20020061840 Tripeptide compounds useful as selective inhibitors of aminopeptidase A and corresponding pharmaceutical compositions |
| 05/23/2002 | US20020061300 Method and composition for treating prostate cancer |
| 05/23/2002 | US20020061292 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria |